Basic Novonorm Information

• INN (International Nonproprietary Name): Repaglinide
• Brand Names Available In United Kingdom: NovoNorm (widely used in Europe) and locally available repaglinide generics.
• ATC Code: A10BX02
• Forms & Dosages: Tablets 0.5 mg, 1 mg, 2 mg.
• Manufacturers In United Kingdom: Novo Nordisk (primary global supplier); other local manufacturers not specified for the UK market.
• Registration Status In United Kingdom: Not specified in the supplied data; NovoNorm is authorised in Europe and repaglinide is prescription-only in all known territories.
• OTC / Rx Classification: Prescription-only medicine (POM).

Critical Warnings & Restrictions

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

• Absolute Contraindications: Type 1 diabetes and diabetic ketoacidosis.
• Drug Contraindication: Concomitant gemfibrozil is contraindicated because of a risk of severe hypoglycaemia.
• Elderly: Increased risk of hypoglycaemia; start low and monitor closely.
• Hepatic Impairment: Contraindicated in severe hepatic impairment; use caution and start at the lowest dose in mild-to-moderate disease.
• Renal Impairment: Start at the lowest dose (0.5 mg) and titrate cautiously with monitoring.
• Pregnancy and Breastfeeding: Avoid unless a diabetes specialist advises otherwise; discuss with a diabetes specialist midwife or consultant.
• Pharmacovigilance: Report suspected adverse reactions via the MHRA Yellow Card.

Practical Patient Checklist:

• Carry a fast-acting glucose source at all times (glucose tablets or sugary snack).
• Wear medical identification stating you take an insulin secretagogue.
• Keep an emergency contact and hypoglycaemia action plan accessible.
• Review all medicines with your pharmacist, especially lipid-lowering or interacting drugs.
• Report suspected side effects through the Yellow Card system.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Hypoglycaemia from repaglinide can impair concentration, reaction times and co-ordination.

Driving and machine operation should only occur if you know you do not get hypoglycaemia and your blood glucose is in a safe range before you start.

The DVLA requires drivers to inform them if they experience recurrent severe hypoglycaemia or loss of hypoglycaemia awareness.

Employers must be informed if a safety-critical role is affected so that a workplace risk assessment can be completed.

Q&A — “Can I Drive After Taking It In The UK?”

Q: Can I drive after taking repaglinide?

A: Only if you know you do not get hypoglycaemia and your blood glucose is safe before driving.

A: If you experience hypoglycaemia, you must not drive and must follow DVLA and NHS guidance.

A: Report severe episodes to your clinician and ensure they are recorded in your medical records.

Usage Basics

INN, Brand Names Available In The UK

• NovoNorm — common European brand for repaglinide tablets.
• Repaglinide generics — locally produced generics available in community and online pharmacies.
• Tablet strengths: 0.5 mg, 1 mg, 2 mg.

ATC Code

A10BX02

Classification

Meglitinide (glinide); rapid-acting prandial insulin secretagogue for type 2 diabetes management.

Legal Classification (POM, P, GSL)

Repaglinide is a prescription-only medicine (POM) in all known territories.

In the UK it must be prescribed by an authorised prescriber under NHS or private prescription rules.

Electronic prescriptions (EPS) are widely used and pharmacists must ensure safe supply and counsel on hypoglycaemia risk and interactions.

Dosing Guide

Standard Regimens (NHS Guidelines)

Initial adult dosing is usually 0.5 mg orally with each main meal if HbA1c is below 8%.

Use 1 mg with each main meal if HbA1c is ≥8% and titrate weekly to effect.

Dose may be increased weekly up to a single dose of 4 mg and a total daily maximum of 16 mg.

Timing Around Meals:

• Take repaglinide 0–30 minutes before each main meal to blunt postprandial glucose spikes.
• If a meal is skipped, skip the dose for that meal; do not double the next dose.

Adjustments For Comorbidities

Start at the lowest dose in elderly patients and in those with renal impairment, with careful monitoring for hypoglycaemia.

Avoid use in severe hepatic impairment and use caution with mild-to-moderate liver dysfunction, starting at the lowest dose and monitoring clinically.

Monitor blood glucose more frequently when combined with other insulin secretagogues or insulin because of additive hypoglycaemia risk.

Q&A — “What If I Miss A Dose?”

Q: What if I miss a dose of repaglinide?

A: If you miss a dose because you skipped the meal, skip that dose and take the next dose with the next main meal.

A: Do not double up doses to make up for a missed one.

A: If unsure, contact your pharmacist or prescriber for personalised advice.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Repaglinide is intended as a mealtime medicine to reduce postprandial glucose peaks, so timing with food is crucial.

Alcohol increases the risk of hypoglycaemia and may blunt warning symptoms and recovery.

Caffeine has no major direct pharmacological interaction but can affect appetite and meal timing, which in turn affects dosing schedules.

Common Drug Conflicts (MHRA Yellow Card Data)

• Gemfibrozil — contraindicated due to risk of severe hypoglycaemia when given with repaglinide.
• Concurrent Insulin Or Sulfonylureas — additive hypoglycaemia risk; monitor closely.
• CYP3A4 And CYP2C8 Modulators — strong inhibitors or inducers may alter repaglinide exposure; consult BNF/MHRA.
• Lipid-Lowering Agents, Antifungals, Macrolides, Protease Inhibitors — review these for interactions and report concerns via Yellow Card.

User Reports & Trends

Patients on NHS.uk leaflets, Patient.info and UK forums report that repaglinide is effective at controlling post-meal glucose for many people.

Users like the mealtime flexibility compared with fixed-dose basal agents when meals are predictable.

Common concerns among users are the risk of hypoglycaemia and the cost depending on brand versus generic supply.

Several patients report repaglinide as a useful option when metformin is contraindicated or poorly tolerated.

Clinically, user-reported adverse effects mirror trial data: hypoglycaemia is the most frequent complaint, followed by occasional gastrointestinal upset and headache.

There is a modest trend in many NHS pathways towards DPP-4 and SGLT2 agents, but repaglinide retains a niche for targeted prandial control.

Pros Reported By Patients:

• Effective control of post-meal glucose spikes.
• Flexibility when meals are regular.
• Alternative when metformin is not suitable.

Cons Reported By Patients:

• Hypoglycaemia risk, especially with missed meals.
• Concerns about cost for brand-name tablets.
• Some report minor GI upset or headache.

Quote (Anonymised): “Novonorm helps with my after-dinner sugars but I always carry glucose tablets just in case.”

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug

Repaglinide (NovoNorm and generics) is available on prescription and can be dispensed at major pharmacy chains such as Boots, LloydsPharmacy and Superdrug, as well as at independent community pharmacies.

Pharmacists will provide counselling, check for drug interactions and advise on hypoglycaemia management.

Because repaglinide is prescription-only, it cannot be bought over the counter in the UK.

Online Pharmacies And NHS E-Prescriptions

The NHS Electronic Prescription Service and online repeat-prescription services allow prescriptions to be sent electronically to a nominated pharmacy.

Licensed online pharmacies registered with the General Pharmaceutical Council (GPhC) will supply repaglinide only against a valid prescription.

Private online clinics may issue private prescriptions but ensure the dispensing pharmacy is registered and provides pharmacist counselling.

Checklist For Verifying An Online Pharmacy:

• GPhC registration and visible pharmacy contact details.
• Secure NHS login or valid prescription handling process.
• Pharmacist contact for counselling and queries.
• Clear privacy and delivery policies.

In our online pharmacy, novonorm is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism & Pharmacology

Simplified Explanation

Repaglinide is a meglitinide, or glinide, which acts as a rapid-acting insulin secretagogue.

It stimulates pancreatic beta cells to release insulin around mealtimes, reducing postprandial glucose peaks.

Because of rapid onset and short duration of action, it is taken immediately before meals for targeted control of prandial glucose.

Clinical Terms

Drug Class

Meglitinide (glinide) — rapid-acting prandial insulin secretagogue.

Pharmacokinetics

Rapid absorption with quick onset and short half-life, making it suitable for mealtime dosing and patients who need targeted prandial control.

Clinical Implication

Useful for patients with predominant postprandial hyperglycaemia or irregular meal schedules when careful counselling can be provided.

Suggested one-line schematic for web use: “Repaglinide → Fast Onset → Insulin Release At Meal → Lower Post-Meal Glucose.”

Indications & Off-Label Uses

MHRA-Approved Uses

Repaglinide is authorised for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults to control postprandial glucose.

It is not indicated for type 1 diabetes or for diabetic ketoacidosis.

Off-Label Practices In NHS And Private Care

• Clinicians may select repaglinide for patients intolerant of metformin or where metformin is contraindicated.
• It may be chosen for patients with predominant postprandial hyperglycaemia or those who need dosing flexibility around meals.
• In elderly patients, off-label use must be individualised and documented with clear justification and informed consent.

Clinician Decision Checklist:

• Document reason for off-label use and expected benefit.
• Review renal and hepatic function before starting.
• Provide written hypoglycaemia and sick-day guidance.

Key Clinical Findings

Randomised trials and comparative studies show repaglinide reduces postprandial glucose and contributes to HbA1c reductions when used alone or in combination therapy.

Comparative data indicate similar HbA1c reductions to sulfonylureas in some studies, although hypoglycaemia profiles vary.

Combination with metformin is commonly studied and frequently used when metformin is tolerated.

• Effective at lowering post-meal glucose peaks.
• Useful as part of combination therapy for HbA1c improvement.
• Hypoglycaemia risk needs to be balanced against benefit, especially in elderly patients.

Research-To-Practice Summary:

Repaglinide offers clear efficacy for prandial control and remains an option in UK practice for patients with mealtime glucose problems or intolerance to first-line agents, with prescribing aligned to MHRA, BNF and local formulary guidance.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Pros: Targeted prandial control, rapid onset, flexible dosing around meals.
• Cons: Hypoglycaemia risk, less effective for fasting hyperglycaemia, contraindicated in severe liver disease and with gemfibrozil.

Common Questions

• Can I drink alcohol while taking repaglinide?

  Alcohol increases the risk of hypoglycaemia and can blunt warning symptoms.

  Avoid binge drinking and discuss usual alcohol intake with your clinician.

• Can repaglinide be used with metformin?

  Yes; combination therapy with metformin is common when metformin alone is insufficient and tolerated.

  Monitor for hypoglycaemia and review renal and hepatic function.

• Is repaglinide safe in pregnancy?

  Repaglinide is not routinely recommended in pregnancy and specialist advice is required.

  Insulin is usually preferred for glucose control in pregnancy; discuss with your obstetric diabetes team.

For NHS pregnancy and diabetes guidance see NHS.uk diabetes in pregnancy pages.

NHS Cost & Access Comparison Table

Check the current NHS prescription charge on NHS.uk and pharmacy price listings before purchase.

How To Claim Exemptions:

• Check NHS eligibility (age, benefits, medical exemptions).
• Use EPS to nominate a pharmacy and set up repeat prescriptions where appropriate.

Registration & Regulation

MHRA Approval Process

Repaglinide formulations such as NovoNorm are authorised under EMA/MHRA pathways for type 2 diabetes.

Prescribers and dispensers should ensure products dispensed are authorised and include the patient information leaflet.

Report suspected adverse reactions via the MHRA Yellow Card scheme.

NHS Prescribing Framework

Prescribing should follow local NHS formularies and any shared care guidelines in place.

The Electronic Prescription Service streamlines prescription delivery but does not change pharmacist counselling responsibilities.

For private prescriptions, document brand/generic choices and patient counselling in the record.

• Licence check for the product being dispensed.
• Confirm contraindications and interacting drugs.
• Advise on Yellow Card reporting for adverse events.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Store repaglinide at 25°C with permitted excursions between 15–30°C.

Protect tablets from moisture and heat, and keep in the original packaging until use.

In UK homes avoid storing medicines in humid or hot places such as bathrooms or near kitchen sinks and radiators.

Guidance From NHS And Pharmacists

Advise patients on transporting medicines during travel and on differences between blister packs and bottles.

Unused or expired repaglinide should be returned to a pharmacy for safe disposal and not thrown in household waste or flushed down the toilet.

Recommended Temperature Range

Store at 25°C; permitted excursions 15–30°C.

Handling

Keep in original pack until needed to protect from moisture.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Counsel on timing: take repaglinide 0–30 minutes before meals to reduce post-meal glucose spikes.

Explain signs of hypoglycaemia and immediate treatment with fast-acting carbohydrate (e.g., glucose tablets or sugary drink).

Confirm missed-dose rules: if the meal is skipped, skip the dose and do not double up.

Highlight important interactions — specifically gemfibrozil is contraindicated — and document counselling.

Encourage patients to use glucose ID and to have a hypoglycaemia emergency plan.

NHS Patient Safety Advice

Monitor HbA1c and review renal and hepatic function periodically while on repaglinide.

Provide written sick-day rules, including when to stop certain glucose-lowering medicines during vomiting or diarrhoea.

Record and review any hypoglycaemia episodes and reassess driving and occupational fitness if needed.

• Symptoms Of Hypoglycaemia: sweating, tremor, confusion, hunger, palpitations.
• Immediate Actions: take 15–20 g of rapid-acting carbohydrate; re-check glucose after 10–15 minutes and repeat if low.
• When To Call 999: if severe confusion, seizures, loss of consciousness or inability to swallow.

Delivery Across United Kingdom

Final Notes

Repaglinide (NovoNorm and generics) is a targeted prandial glucose regulator effective for post-meal control in adults with type 2 diabetes.

Choice of therapy should balance glycaemic benefit against hypoglycaemia risk, especially in elderly patients and those with hepatic or renal impairment.

Always follow MHRA, BNF and local formulary guidance when prescribing or dispensing repaglinide and report suspected safety issues via Yellow Card.

For personalised advice, consult your GP, diabetes specialist or pharmacist and ensure you have an up-to-date hypoglycaemia action plan.